Cigarettes with ultralow nicotine levels are now being called the game-changer in the fight against smoking. If you are having trouble in quitting smoking, then, it is for you, that soon the Biden White House is expected to formally propose a plan that will order cigarette nicotine levels to be reduced, reports The Washington Post. For now though, it has been a failure, as these cigarettes, also known as VLN cigarettes that stands for very low nicotine are only available in 5,100 stores in 26 states. This is a very small fraction of the overall market for cigarettes. The company that makes it, 22nd Century, is struggling not because of the low supply, but also from the advocates who have long believed slashing nicotine levels altogether.

The Advent and ideation

Nicotine is a chemical that is produced naturally from tobacco that makes the cigarette and also keeps people hooked. While it is believed that it makes people alert, and get the "hit" to keep them going, it exposes the users to harmful substances, carcinogens, and increases the risk of heart disease, lung cancer, and other illness.

Ultralow-nicotine cigarettes, like the VLN brand, contain about 95% less nicotine than the regular cigarettes. The idea is quite simple: without the addictive grip of nicotine, smokers will find it easier to quit. Research too has shown some promise. For instance, the studies funded by the National Institute on Drug Abuse revealed that very low nicotine cigarettes reduced addiction potential significantly without having users to increase their smoking frequency. However, the problem is, why would anyone choose for a low-nicotine that does not make them feel the same way, when the high-nicotine cigarette is right next to it, making them feel the same way, with the same alertness, sold at the same price.

“It’s very hard to imagine someone actively choosing to continue to use a low-nicotine product for the same price when a high-nicotine product is right next to it,” said Eric Donny, a Wake Forest University School of Medicine nicotine researcher.

No wonder, the experiment with low nicotine product by Philip Morris' Next cigarettes in the 1980s and Vector Tobacco's Quest brand in the early 2000s, flopped.

FDA's Role in the Push

The Food and Drug Administration (FDA) has supported the development of such products, even allowing VLN cigarettes to be marketed as lower-risk options. However, these products remain a niche market, available in only a fraction of U.S. stores.

Recently, the Biden administration has considered a bold step—mandating a dramatic reduction in nicotine levels for all cigarettes sold in the United States. Supporters believe this move could save millions of lives, while critics, including tobacco companies, warn of potential unintended consequences.

What Could Be The Challenges?

Resistance from Big Tobacco Companies: They could argue that slashing nicotine levels could backfire. Their claim is, smokers will turn to black markets or smoke more to satisfy their cravings, which may lead to greater exposure to harmful substances.

Consumer Reluctance: History is proof to the instances of smokers being hesitant to embrace the low-nicotine products.

Political Hurdle: It may face political roadblocks, as under the Trump administration, plans to cut nicotine were shelved.

Could Low-Nicotine Cigarettes Be The Solution?

Advocates believe that ultralow-nicotine cigarettes could be a game-changer, comparing them to decaf coffee or non-alcoholic beer—products that reduce harm while offering a similar experience.

Some experts warn that a black market for traditional cigarettes could undermine these efforts. They also stress the need for safer alternatives, such as vaping products, to support smokers transitioning away from traditional cigarettes.

Propranolol is a beta-blocker that is used to address certain heart conditions and physical symptoms of anxiety. It has been gaining attention on social media for calming nerves before stressful life events like job interviews, presentations and other similar situations.

However, experts warn that its surging popularity may make it difficult to pay attention to the limited evidence supporting its use for anxiety.

The medication works by blocking the effects of adrenaline on beta receptors, slowing the heart rate and reducing physical symptoms like trembling, sweating and palpitations. It does not directly treat the emotional symptoms of anxiety.

Propranolol Has Becoming Popular As A 'Quick Fix'

In England, the NHS dispensed around 8.4 million propranolol prescription items in the 12 months leading up to June 2026, a 4.7% increase from the previous year. These figures cover all uses of the drug, not just anxiety.

Significant increases in prescriptions among younger women and teenage girls over a decade was also seen. Social media has helped promote propranolol as a quick fix for nerves, but its popularity does not reflect the strength of its clinical evidence.

Also read: Seasonal Depression & Anhedonia: How Winter Can Affect Pleasure And Motivation

What Does The Evidence Say?

Dr Daniel Gordon, private GP and managing director at DGA Health told Daily Mail that propranolol may help people whose anxiety mainly causes physical symptoms.

"In my experience, the people who find propranolol helpful are usually those whose anxiety shows up mostly in the body, with palpitations, shaking and a pounding chest," Dr Gordon said.

He also said that addressing those symptoms can treat physical symptoms, helping people feel more in control. But feeling calmer in the body is not the same as treating anxiety, and for many people talking therapies, and sometimes other medicines, prove to be helpful.

Additionally, the evidence available on Propranolol is insufficient contrary to its online popularity. A systematic review of eight small randomised trials, covering around 200 people, concluded that the evidence was insufficient to support routine use of propranolol in any anxiety disorder.

Some people do report relief of physical symptoms, but propranolol us not recommended for anxiety as there are no modern, reliable clinical trials.

Dr Gordon added, "This is exactly why proper assessment matters. Propranolol should generally not be used by people with asthma, certain heart rhythm problems such as heart block, a very slow heart rate or low blood pressure, and it can mask the warning signs of low blood sugar in people with diabetes."

Also read: The Silent Struggle Of Raising A Child With Mental Health Challenges: How Parents Can Cope With Stigma

Risks Of Taking Propranolol Without Prescription

Common side effects of propranolol include dizziness, tiredness, cold hands and feet, and sleep disturbances. Because propranolol can decrease heart rate and blood pressure, it may be unsuitable for people with low blood pressure. It can also be risky for people with asthma and heart conditions.

Buying prescription medication online is not inherently unsafe, but a brief questionnaire does not necessarily mean that a person's medical history and individual risks have been adequately assessed.

Gordon stressed that a medical doctor needs to review a patient's medical history before prescribing the drug as it can interact with other medications and may be unsuitable for some patients.

Alternatives For Managing Anxiety

Propranolol may help some people manage physical symptoms in some situations, but it is not a substitute for treating clinical anxiety.

Psychological therapies, including cognitive behavioural therapy (CBT), can help people manage anxious thoughts. Medication may also be appropriate depending on the person's symptoms.

People whose anxiety affects their work, relationships or daily activities should speak to a healthcare professional rather than taking propranolol.

Police in Guinea-Bissau raided the Bandim Health Project on Monday, October 19, and seized a batch of hepatitis B vaccines intended for a controversial trial involving 14,000 newborns, according to an official statement.

The project’s Danish researchers, Peter Aaby and Christine Stabell Benn, are at the center of the dispute. The study received $1.6 million from the US Centers for Disease Control and Prevention (CDC), matched by the Pershing Square Foundation and the Bluebell Foundation, bringing total funding to $3.2 million. US Health and Human Services Secretary Robert F. Kennedy Jr. has praised the researchers’ work.

The police search took place on Monday, involving “investigative procedures aimed at clarifying the circumstances related to the said batch of vaccines”, according to the social media post, which was translated from Portuguese. The announcement noted that seizing the immunizations did not point to “irregularities in the quality, safety, or effectiveness of the vaccines”, The Guardian reported.

Why Is the Hepatitis B Vaccine Trial Controversial?

The proposed trial would randomly divide 14,000 newborns into two groups: one would receive the hepatitis B vaccine at birth, while the other would receive it six weeks later.

The WHO recommends hepatitis B vaccination within 24 hours of birth to prevent mother-to-child transmission.

Why Is Delaying Vaccination a Concern?

Also read: Hepatitis B Infections Could Rise 83% If US Changes Newborn Vaccine Policy: Study

Hepatitis B is highly endemic in Guinea-Bissau, affecting more than 12% of adults. Infants infected at birth have about a 90% chance of developing chronic infection, which can lead to cirrhosis, liver failure and liver cancer.

Stig Børsen Hansen, a member of the University of Southern Denmark’s ethics committee, resigned after the committee narrowly approved the updated protocol. He warned that the trial would expose some newborns to potentially serious infections by delaying vaccination.

What Is the Study Investigating?

Rather than testing the vaccine’s established efficacy, the study aims to investigate the proposed “non-specific effects” of vaccines — potential health effects beyond protection against targeted infections.

Critics argue that delaying a recommended birth dose to investigate these hypotheses exposes newborns to avoidable risks. Former Guinea-Bissau Health Minister Magda Robalo and other critics have also raised concerns about conducting such research in a vulnerable population.

What Have Authorities Said?

The Bandim Health Project published an approval letter from Guinea-Bissau’s national ethics committee, dated July 14. A Danish research ethics committee also approved the study earlier this month.

However, transitional government Health Minister Quinhin Nantote disputed reports that the trial would proceed, telling The Guardian: “This is not even remotely true.”

WHO spokesperson Tarik Jašarević said a study denying newborns the vaccine would be “unethical” and expose them to “serious and potentially irreversible harm.” The WHO is advising Guinea-Bissau’s Ministry of Health on introducing the vaccine and assessing the study’s potential impact.

Why Is RFK Jr. Backing the Researchers?

Anthropologist Peter Aaby founded the Bandim Health Project in 1978. It is now co-led by his wife, epidemiologist Christine Stabell Benn.

Kennedy has called the pair “the deities of vaccine research” at an anti-vaccine conference and cited their research on the diphtheria-tetanus-pertussis (DTP) vaccine. A subsequent study by the researchers produced different results.

Kennedy also called Aaby a “very famous” researcher on Joe Rogan’s podcast in 2023 and cited his work when he halted US funding to Gavi, the Vaccine Alliance.

Stabell Benn served on the hepatitis B working group of the US Advisory Committee on Immunization Practices (ACIP) and presented evidence before the committee voted to end the universal hepatitis B birth-dose recommendation. A federal judge subsequently stayed the decision.

With digital innovation, expanding healthcare access, and a growing focus on self-reliance driving transformation in India's healthcare sector, the Times Network India Health Summit & Awards 2026 is set to return for its third edition.

The event, to be held on October 28th, will bring together policymakers, healthcare leaders, clinicians, researchers, innovators, and industry stakeholders to discuss the future of India's healthcare ecosystem.

Centered on the theme, “The Blueprint for a Future-Ready Healthcare Ecosystem – Innovation. Access. Self-Reliance,” the summit will explore emerging healthcare innovations, collaborations, and policy approaches, culminating in an awards ceremony recognizing excellence across the sector.

As India is advancing in artificial intelligence (AI), digital health, biotechnology, medical technology (MedTech), and indigenous manufacturing, these areas will also be central to discussions on strengthening the country's healthcare ecosystem.

Summit At A Glance

Anupriya Patel, Union Minister of State for Health and Family Welfare and Minister of State for Chemicals and Fertilizers, is expected to attend as the chief guest.

The second edition of the Times Network India Health Summit & Awards 2026 will feature:

• 30+ speakers
• 400+ delegates
• 12+ knowledge sessions

Six Key Healthcare Discussion Areas

The summit will feature six panel discussions covering key areas of healthcare innovation, access, and policy.

• Advanced Healthcare Infrastructure And Clinical Excellence: Scaling advanced care through AI, Centres of Excellence, and digital innovation.
• Fertility And Reproductive Healthcare: Exploring reproductive technologies, precision medicine, and patient access.
• India's Biopharma Growth: Advancing research, therapeutics, and resilient manufacturing.
• Precision Diagnostics: Leveraging AI, genomics, and personalized care.
• Integrative Healthcare: Strengthening scientific research and AYUSH integration.
• Healthcare Financing: Improving affordability, access, and sustainability through insurance and public-private partnerships.

The summit is being held in association with Onextel Communications Media, co-powered by Novartis and supported by HealthandMe. It will conclude with a felicitation ceremony recognizing excellence across the healthcare sector.